NEW YORK (GenomeWeb) – Enzo Biochem said on Monday that its revenues for its fiscal third quarter were up 6 percent year over year.

For the three months ended April 30, the company reported total revenues of $24 million, up from $22.6 million in the year-ago quarter. Enzo's Clinical Labs segment revenues rose to 9 percent $14.5 million from $13.4 million, while Life Science product revenues increased 5 percent to $8.7 million from $8.3 million. Royalty and licensing fee income slid to $729,000 from $949,000.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.